AzTrials
AzTrials

Painful Diabetic NeuropathyPhase 2NCT00695565

Efficacy and Safety Study of ARC-4558 for Management of Pain Associated With Painful Diabetic Neuropathy

A Phase 2 study testing Clonidine Topical Gel (ARC-4558) in people with Painful Diabetic Neuropathy, run by Arcion Therapeutics Inc at 16 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to determine whether ARC-4558 is effective in managing pain associated with painful diabetic neuropathy. Read more about this study

Who is it for?
Ages 18 to 80 years
Conditions the study is for
Painful Diabetic Neuropathy
What is being tested?
Clonidine Topical Gel (ARC-4558)
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
180 participants
Where
16 sitesUnited States
Study dates
May 2008to Feb 2010
Phase
Phase 2
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • has Type 1 or Type 2 diabetes mellitus
  • has a history of chronic pain attributable to a symmetrical stocking distribution neuropathy in the lower extremities for a duration of at least six months but less than or equal to five years prior to Screening

Who cannot join

  • has neuropathy secondary to non-diabetic causes
  • has a significant neurological disorder or a condition that can cause symptoms that mimic peripheral neuropathy or might confound assessment of PDN
  • has other chronic pain with intensity at or greater than the bilateral pain in the feet/toes
  • is using an implanted medical device (eg, spinal cord stimulator, intrathecal pump, or peripheral nerve stimulator) for the treatment of pain
  • is pregnant or lactating

Trial locations and contacts

16 sites in 1 country.

16 sites in 1 country

United States16 sites
  • University of Alabama at Birmingham, School of Medicine

    Birmingham, Alabama, 35294

  • Cleveland Clinic

    Cleveland, Ohio, 44195

  • The Nerve and Muscle Center of Texas

    Houston, Texas, 77030

  • Pain Treatment Center of the Bluegrass

    Lexington, Kentucky, 40503

  • Waccamaw Pain Partners/Crescent Moon Research

    Murrells Inlet, South Carolina, 29576

  • Tulane University Health Sciences Center

    New Orleans, Louisiana, 70112

  • Strelitz Diabetes Institute, Eastern Virginia Medical School

    Norfolk, Virginia, 23510

  • The Creighton Diabetes Center

    Omaha, Nebraska, 68131

  • University of Rochester Medical Center

    Rochester, New York, 14642

  • Northern California Research

    Sacramento, California, 95821

  • Diabetes and Glandular Disease Center

    San Antonio, Texas, 78229

  • Neurological Research Institute

    Santa Monica, California, 90404

  • Swedish Pain Center

    Seattle, Washington, 98104

  • Metabolic Research Institute

    West Palm Beach, Florida, 33401

  • The Center for Clinical Research

    Winston-Salem, North Carolina, 27103

  • University of Massachuetts Medical School, Division of Diabetes- Clinical Research Office

    Worcester, Massachusetts, 01655

Other trials in United States

About this study

Official title: A Multicenter, Randomized, Double-Blind, Parallel-Group Study Comparing the Efficacy and Safety of Clonidine Topical Gel, 0.1% With Placebo in the Management of Pain Associated With Painful Diabetic Neuropathy

The purpose of this study is to determine whether ARC-4558 is effective in managing pain associated with painful diabetic neuropathy.

Being tested
Placebo Gel, Clonidine Topical Gel (ARC-4558)
Medical subject headings
Diabetic Neuropathies

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Placebo GelDrug

    TID x 12 weeks

  • Clonidine Topical Gel (ARC-4558)Drug

    TID x 12 weeks

Study groups in NCT00695565
Study groupRoleWhat they receive
Placebo GelPlacebo comparatorPlacebo Gel is vehicle without clonidine
Receives: Drug: Placebo Gel
Clonidine Topical Gel (ARC-4558)Active comparatorClonidine Topical Gel contains 0.1% clonidine hydrochloride
Receives: Drug: Clonidine Topical Gel (ARC-4558)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change From Baseline to Week 12 in the Average Daily Pain NPRS (Numeric Pain Rating Scale) Score; mLOCF Imputation

    Pain in the feet was scored daily at bedtime by the subject on a 0-10 numeric pain rating scale (NPRS) through Day 84. Subjects were asked to record average pain in the feet over the past 24 hours. A score of 0 indicated "no pain" and a score of 10 was "worst possible pain".

    The change in pain is represented as Week 12 minus Baseline, so greater negative numbers represent more improvement (more pain relief).

    Measured: Baseline (average of Days -7 to -1) and Week 12 (Average of Days 78 to 84)

Secondary outcomes (13)
  1. Change From Baseline in Average Daily Pain NPRS Score for Each Week of Treatment; mLOCF Imputation

    Pain in the feet was scored daily at bedtime by the subject on a 0-10 numeric pain rating scale (NPRS). Subjects were asked to record average pain in the feet over the past 24 hours. A score of 0 indicated "no pain" and a score of 10 was "worst possible pain". A weekly average was calculated from the daily scores for each week. The change in pain is represented as the average weekly score minus Baseline, so greater negative numbers represent more improvement (more pain relief).

    Measured: Baseline (average of Days -7 to -1) and Weeks 1 through 12 (weekly averages)

  2. Change From Baseline to Week 12 in the Worst Daily Pain NPRS Score; mLOCF Imputation

    Pain in the feet was scored daily at bedtime by the subject on a 0-10 numeric pain rating scale. Subjects were asked to record the worst pain in their feet over the past 24 hours. A score of 0 indicated "no pain" and a score of 10 was "worst possible pain". The change in pain is represented as Week 12 minus Baseline, so greater negative numbers represent greater improvement (greater pain relief).

    Measured: Baseline (average of Days -7 to -1) and Week 12 (average of Days 78 to 84)

  3. Percentage of Subjects Who Experience at Least 30% Reduction in Average Daily Pain From Baseline; mLOCF Imputation

    Pain in the feet was scored daily at bedtime by the subject on a 0-10 numeric pain rating scale (NPRS). Subjects were asked to record average pain in the feet over the past 24 hours. A score of 0 indicated "no pain" and a score of 10 was "worst possible pain".

    Measured: Baseline (average of Days -7 to -1) and Week 12 (average of Days 78 to 84)

  4. Percentage of Subjects Who Experience at Least 50% Reduction in Average Daily Pain From Baseline; mLOCF Imputation

    Pain in the feet was scored daily at bedtime by the subject on a 0-10 numeric pain rating scale (NPRS). Subjects were asked to record average pain in the feet over the past 24 hours. A score of 0 indicated "no pain" and a score of 10 was "worst possible pain".

    Measured: Baseline (average of Days -7 to -1) and Week 12 (average of Days 78 to 84)

  5. Change From Baseline in the Brief Pain Inventory (BPI) Severity Scale at Week 12; mLOCF Imputation

    The Brief Pain Inventory was completed by the subject at clinic visits. The Severity Scale (of 0 to 40) is a composite score, which is the sum of the individual ratings for worst pain, least pain, average pain, and current pain. Each individual question is rated on a scale of 0 to 10, where 0 indicates "No Pain" and 10 indicates "Pain as bad as you can imagine". The change in pain severity is represented as Week 12 minus Baseline, so greater negative numbers represent greater improvement (pain relief).

    Measured: Baseline and Week 12

  6. Change From Baseline in the Brief Pain Inventory Functional Interference Scale at Week 12; mLOCF Imputation

    The Brief Pain Inventory was completed by the subject at clinic visits. The Functional Interference Scale (of 0 to 70) is a composite score that measures the degree to which pain interferes with mood, walking, work, relationships, sleep, general activity, and enjoyment of life. The composite score is a sum of the seven individual question scores. Each individual question is rated in reference to pain over the past 24 hours on a scale of 0 to 10, where 0 indicates that pain "does not interfere" and 10 indicates that pain "completely interferes" with that function, so lower scores represent better outcomes on this scale.

    The change in functional interference is represented as Week 12 minus Baseline, so greater negative numbers represent more improvement.

    Measured: Baseline and Week 12

  7. Change From Baseline to Week 12 in Overall Quality of Sleep (Chronic Pain Sleep Inventory)

    Subjects rated overall quality of sleep over the past week using a 100 mm Visual Analog Scale (VAS) where 100=Excellent and 0=Very Poor. This scale was completed during clinic visits. Change from Baseline is a positive value where quality of sleep improved.

    Measured: Baseline and Week 12

  8. Change From Baseline to Week 12 in the Depression Score of the Hospital Anxiety and Depression Scale (HADS)

    The HADS was completed at the Baseline and Week 12 clinic visits. The Depression Score component of the HADS includes 7 questions, each with 4 possible answer choices (rated 0 to 3). The composite score is created by adding the scores of the 7 individual questions. A score of 0 to 7 is Normal, 8-10 indicates Mild Depression, 11-14 indicates Moderate Depression, and 15-21 indicates Severe Depression. The change from Baseline is calculated as the Week 12 composite score minus the Baseline composite score.

    Measured: Baseline and Week 12

  9. Change From Baseline to Week 12 in the Anxiety Score of the Hospital Anxiety and Depression Scale (HADS)

    The HADS was completed at the Baseline and Week 12 clinic visits. The Anxiety Score component of the HADS includes 7 questions, each with 4 possible answer choices (rated 0 to 3). The composite score is created by adding the scores of the 7 individual questions. A score of 0 to 7 is Normal, 8-10 indicates Mild Anxiety, 11-14 indicates Moderate Anxiety, and 15-21 indicates Severe Anxiety. The change from Baseline is calculated as the Week 12 composite score minus the Baseline composite score.

    Measured: Baseline and Week 12

  10. Change From Baseline to Week 12 in the McGill Pain Questionnaire (Short Form) Total Score

    The McGill Pain Questionnaire asks subjects to rate 15 different kinds of pain, each on a scale of 0 to 3 (0=None, 1=Mild, 2=Moderate, 3=Severe). The total score is a sum of the individual ratings and has a range from 0 to 45, where higher numbers indicate more pain. The 15 types of pain assessed are throbbing, shooting, stabbing, sharp, cramping, gnawing, hot-burning, aching, heavy, tender, splitting, tiring-exhausting, sickening, fearful, and punishing-cruel. This scale was completed at the Baseline and Week 12 clinic visits. The change from Baseline is calculated as the Week 12 total score minus the Baseline total score, so greater negative numbers indicate more improvement (pain relief).

    Measured: Baseline and Week 12

  11. Patient Global Impression of Change (PGIC) at Week 12

    At Week 12 the subject was asked to rate their total improvement relative to Baseline, whether or not, in their judgement, it was due entirely to study drug treatment or not. Answer choices were: (+3) very much improved, (+2) much improved, (+1) minimally improved, (0) no change, (-1) minimally worse, (-2) much worse, (-3) very much worse.

    Measured: Week 12

  12. Clinician Global Impression of Change (CGIC) at Week 12

    At Week 12, the Investigator was asked to independently rate the subject's total improvement relative to Baseline, whether or not, in their judgement, it was due entirely to study drug treatment or not. Answer choices were: (+3) very much improved, (+2) much improved, (+1) minimally improved, (0) no change, (-1) minimally worse, (-2) much worse, (-3) very much worse.

    Measured: Week 12

  13. Change in Blood Pressure From Baseline to Week 12

    Systolic and Diastolic Blood Pressure were measured at clinic visits. This outcome assesses the change in blood pressure from Baseline to Week 12 of treatment.

    Measured: Baseline and Week 12

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Jun 2008 (estimated)
  2. Study startMay 2008
  3. Primary completionDec 2009
  4. Study completionFeb 2010

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
180 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00695565
Sponsor's protocol ID
CLO-027
Status last verified
Sep 2016
First submitted
10 Jun 2008
Last updated
8 Nov 2016
Data monitoring committee
Yes
Individual data sharing
Undecided

Publications

  • Campbell CM, Kipnes MS, Stouch BC, Brady KL, Kelly M, Schmidt WK, Petersen KL, Rowbotham MC, Campbell JN. Randomized control trial of topical clonidine for treatment of painful diabetic neuropathy. Pain. 2012 Sep;153(9):1815-1823. doi: 10.1016/j.pain.2012.04.014. Epub 2012 Jun 8.

    PubMed 22683276
  • Serednicki WT, Wrzosek A, Woron J, Garlicki J, Dobrogowski J, Jakowicka-Wordliczek J, Wordliczek J, Zajaczkowska R. Topical clonidine for neuropathic pain in adults. Cochrane Database Syst Rev. 2022 May 19;5(5):CD010967. doi: 10.1002/14651858.CD010967.pub3.

    PubMed 35587172

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Clonidine Topical Gel (ARC-4558) in people with Painful Diabetic Neuropathy, run by Arcion Therapeutics Inc at 16 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 8 Nov 2016. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 16 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 8 Nov 2016). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change From Baseline to Week 12 in the Average Daily Pain NPRS (Numeric Pain Rating Scale) Score; mLOCF Imputation (time frame: Baseline (average of Days -7 to -1) and Week 12 (Average of Days 78 to 84)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00695565, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Nov 2016.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in